This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo


Oral formulations of cinnarizine.

Drugs List

  • cinnarizine 15mg tablets
  • STUGERON 15 tablets
  • Therapeutic Indications


    Labyrinthine disorders
    Motion sickness

    For the control of labyrinthine disorders such as vertigo, tinnitus, nystagmus, nausea and vomiting such is as seen in Meniere's disease.

    Prophylaxis and control of motion sickness.


    It is recommended that cinnarizine is taken after meals to minimise gastric discomfort.


    Vestibular symptoms:
    30 mg three times a day.

    Motion sickness:
    30 mg two hours before travelling and then 15 mg every 8 hours during the journey if necessary.


    Vestibular symptoms:
    30 mg three times a day

    Motion sickness:
    30 mg two hours before travelling and then 15 mg every 8 hours during the journey if necessary.


    Children may be more susceptible to side effects.

    Vestibular symptoms:
    Children over 12 years :
    30 mg three times a day

    Children 5 to 12 years:
    15 mg three times a day

    Motion sickness:
    Children over 12 years:
    30 mg two hours before travelling and then 15 mg every 8 hours during the journey if necessary.

    Children 5 to 12 years:
    15 mg two hours before travelling and then 7.5 mg every 8 hours during the journey if necessary.


    Children under 5 years

    Precautions and Warnings

    Benign prostatic hyperplasia
    Epileptic disorder
    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    Hereditary fructose intolerance
    Lactose intolerance
    Narrow angle glaucoma
    Parkinson's disease
    Pyloroduodenal obstruction
    Renal impairment
    Urinary retention

    Advise ability to drive/operate machinery may be affected by side effects
    Not all available brands are indicated for all uses
    Some formulations contain lactose
    Some formulations contain sucrose
    Treatment may prevent a positive reaction to dermal reactivity indicators
    Discontinue if extrapyramidal effects occur
    Advise that effects are potentiated by CNS depressants (including alcohol)
    Advise patient to take after food to reduce gastro-intestinal disturbances

    Rare case of aggravation or appearance of extrapyramidal symptoms have occurred predominantly in the elderly. Treatment should be discontinued in such cases.

    Pregnancy and Lactation


    Cinnarizine should be used with caution in pregnancy.

    The manufacturer does not recommend the use of cinnarizine in pregnancy.

    However, cinnarizine has shown no increase in birth defects after clinical use and Briggs' considers cinnarizine compatible with pregnancy.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Cinnarizine is contraindicated in breastfeeding.

    At the time of writing there is no data on use of cinnarizine in breastfeeding. The molecular weight and elimination half-life suggest that the drug will be excreted into breast milk. A risk neonates cannot be excluded.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Aggravation of extrapyramidal symptoms
    Blood disorders
    Blurred vision
    Cholestatic jaundice
    Dry mouth
    Excitement (paradoxical)
    Extrapyramidal effects
    Gastro-intestinal disturbances
    Glaucoma (closed angle)
    Hypersensitivity reactions
    Lichen planus
    Lichenoid keratosis
    Lupus erythematosus-like syndrome
    Muscle rigidity
    Psychomotor impairment
    Sleep disturbances
    Upper abdominal pain
    Urinary retention
    Weight gain


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2014

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Joint Formulary Committee. British National Formulary(online) London: BMJ Group and Pharmaceutical Press. Accessed on 12 December 2014.

    Martindale: The Complete Drug Reference, 37th edition (2011) ed. Sweetman, S. Pharmaceutical Press, London.

    Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications. Accessed on 12 December 2014.

    Summary of Product Characteristics: Cinnarizine 15mg. Janssen-Cilag Ltd. Revised July 2010.

    Summary of Product Characteristics: Mylan Travel Sickness Tablets. Generics (UK) Ltd. Revised November 2011.

    Summary of Product Characteristics: Stugeron 15mg. Janssen-Cilag Ltd. Revised May 2020.

    Summary of Product Characteristics: Stugeron 15. McNeil Products Ltd. Revised August 2014.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.